GeNeuro has entered into a strategic partnership with Servier to develop and market GNbAC1 in Multiple Sclerosis Read the full story

Intarcia Therapeutics announced the successful start of a strategic partnership with Servier outside the United States and Japan, to develop and commercialize ITCA 650 Read the full story

The term 'top pharma' can relate to the top pharmaceutical companies or the top 10 or 50... Read the full story

Servier is a top pharmaceutical company based in Suresnes, France Read the full story

Servier have signed a strategic global collaboration agreement with Novartis to develop and commercialize a series of novel drugs candidates issued from the Servier research programs partnered with Vernalis in oncology which are targeting the apoptosis regulation pathways. Read the full story

Clovis Oncology acquires Ethical Oncology Science for $420 million and a enters into a licensing deal for Lucitanib with Servier for $470 million. Read the full story

XENTION and SERVIER pharma partners by entering into a multi-year agreement for the development and commercialisation of XEN-D0103, a selective Kv1.5 modulator discovered and developed by Xention for the treatment of atrial fibrillation Read the full story

French big pharma giant Servier has offered to buy the shares in Hungarian pharmaceuticals maker Egis creating M&A news Read the full story

Servier is a European research based pharmaceutical company focusing on the areas of oncology, cardiovascular and Central Nervous System diseases.

Read the full story

Servier is a top independent pharmaceutical company committed to progressing medicine.  The company’s partnering, collaborative R&D and licensing activities are reviewed here Read the full story